Catalent, Inc. (NYSE:CTLT) Shares Purchased by Citigroup Inc.

Citigroup Inc. lifted its holdings in Catalent, Inc. (NYSE:CTLT) by 26.2% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 204,923 shares of the company’s stock after purchasing an additional 42,517 shares during the quarter. Citigroup Inc. owned 0.11% of Catalent worth $12,412,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of CTLT. O Shaughnessy Asset Management LLC acquired a new position in Catalent during the 1st quarter valued at about $214,000. California State Teachers Retirement System raised its holdings in Catalent by 0.4% during the first quarter. California State Teachers Retirement System now owns 284,815 shares of the company’s stock worth $16,078,000 after purchasing an additional 1,149 shares in the last quarter. Swedbank AB acquired a new stake in Catalent in the first quarter worth approximately $1,659,000. DekaBank Deutsche Girozentrale boosted its stake in Catalent by 2.4% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 31,445 shares of the company’s stock valued at $1,763,000 after purchasing an additional 732 shares in the last quarter. Finally, GAMMA Investing LLC increased its position in shares of Catalent by 25.9% during the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after purchasing an additional 212 shares during the period.

Analysts Set New Price Targets

CTLT has been the subject of several research analyst reports. StockNews.com lowered Catalent from a “hold” rating to a “sell” rating in a report on Friday, November 22nd. Robert W. Baird reaffirmed a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. William Blair reissued a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Finally, Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating and seven have issued a hold rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $63.40.

Insider Buying and Selling

In other news, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. This represents a 5.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the sale, the director now owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. This represents a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,114 shares of company stock valued at $305,931. Corporate insiders own 0.31% of the company’s stock.

Catalent Stock Performance

Catalent stock opened at $61.00 on Friday. Catalent, Inc. has a fifty-two week low of $36.74 and a fifty-two week high of $61.50. The firm’s 50 day simple moving average is $59.86 and its 200-day simple moving average is $58.41. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. The company has a market cap of $11.07 billion, a P/E ratio of -26.99, a price-to-earnings-growth ratio of 2.44 and a beta of 1.16.

Catalent (NYSE:CTLT) last announced its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.18). The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. Catalent’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.10) earnings per share. As a group, equities research analysts predict that Catalent, Inc. will post 0.84 EPS for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.